News report quoting US Senator Chuck Grassley (a coauthor of the Preserve Access to Affordable Generic Drugs Act) as stating that brand name pharmaceutical manufacturers are continuing to pay generic drug makers to keep their products out of the US market.  This followed the release in Oct 2011 of a US Federal Trade Commission (FTC) report on patent agreements filed in fiscal year 2011.  The FTC received 156 final resolutions of patent disputes between manufacturers of brand-name drugs vs generic drug makers; of these, 28 final settlements involved both compensation to the generic manufacturer and a restriction on the generic manufacturer's ability to market its product.  These settlements involved 25 different brand name pharmaceutical products with combined annual US sales of more than $9 billion.